Egypt

Egypt

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.96 (1.56 - 2.43) 2015 Modelled WHO
1 (0.90 - 1.20) 2016 Modelled Razavi-Shearer et al, 2018
1.71 (1.67 - 1.76) 2013 Modelled Schweitzer et al, 2015
1.4 (1.20 - 1.60) 2015 Survey/reported Ismail et al, 2017
1 2015 Survey/reported Ministry of Health et al, 2015
1 2022 Modelled The Polaris Observatory Collaborators, 2023
3.61 (3.43 - 3.84) 2019 Modelled IHME, GBD 2019 (accessed 2020)
4.1 (3.89 - 4.34) 2018 Modelled IHME, GBD 2019 (accessed 2022)
4.16 (3.90 - 4.43) 2017 Modelled IHME, GBD 2019 (accessed 2022)
4.3 (4.06 - 4.54) 2016 Modelled IHME, GBD 2019 (accessed 2022)
4.4 (4.16 - 4.69) 2015 Modelled IHME, GBD 2019 (accessed 2022)
4.45 (4.22 - 4.72) 2014 Modelled IHME, GBD 2019 (accessed 2022)
4.57 (4.32 - 4.82) 2013 Modelled IHME, GBD 2019 (accessed 2022)
4.71 (4.45 - 4.97) 2012 Modelled IHME, GBD 2019 (accessed 2022)
4.84 (4.54 - 5.11) 2011 Modelled IHME, GBD 2019 (accessed 2022)
4.9 (4.57 - 5.22) 2010 Modelled IHME, GBD 2019 (accessed 2022)
4.94 (4.63 - 5.26) 2009 Modelled IHME, GBD 2019 (accessed 2022)
5.03 (4.73 - 5.35) 2008 Modelled IHME, GBD 2019 (accessed 2022)
5.13 (4.84 - 5.46) 2007 Modelled IHME, GBD 2019 (accessed 2022)
5.22 (4.93 - 5.56) 2006 Modelled IHME, GBD 2019 (accessed 2022)
5.27 (4.96 - 5.62) 2005 Modelled IHME, GBD 2019 (accessed 2022)
5.31 (5 - 5.65) 2004 Modelled IHME, GBD 2019 (accessed 2022)
5.4 (5.12 - 5.74) 2003 Modelled IHME, GBD 2019 (accessed 2022)
5.51 (5.22 - 5.85) 2002 Modelled IHME, GBD 2019 (accessed 2022)
5.6 (5.29 - 5.95) 2001 Modelled IHME, GBD 2019 (accessed 2022)
5.64 (5.30 - 6.01) 2000 Modelled IHME, GBD 2019 (accessed 2022)
5.66 (5.34 - 6.03) 1999 Modelled IHME, GBD 2019 (accessed 2022)
5.72 (5.39 - 6.08) 1998 Modelled IHME, GBD 2019 (accessed 2022)
5.78 (5.43 - 6.16) 1997 Modelled IHME, GBD 2019 (accessed 2022)
5.84 (5.48 - 6.23) 1996 Modelled IHME, GBD 2019 (accessed 2022)
5.87 (5.49 - 6.26) 1995 Modelled IHME, GBD 2019 (accessed 2022)
5.88 (5.51 - 6.26) 1994 Modelled IHME, GBD 2019 (accessed 2022)
5.9 (5.53 - 6.29) 1993 Modelled IHME, GBD 2019 (accessed 2022)
5.95 (5.55 - 6.34) 1992 Modelled IHME, GBD 2019 (accessed 2022)
6 (5.58 - 6.40) 1991 Modelled IHME, GBD 2019 (accessed 2022)
6.06 (5.60 - 6.48) 1990 Modelled IHME, GBD 2019 (accessed 2022)
4.05 (3.84 - 4.30) 2019 Modelled IHME, GBD 2019 (accessed 2022)
0.9 (0.70 - 1.10) 2022 Modelled Polaris Observatory Collaborators
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.8 (0.54 - 1.10) 2015 Modelled WHO
0.11 (0.09 - 0.13) 2019 Modelled IHME, GBD 2019 (accessed 2020)
0.14 (0.11 - 0.16) 2019 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2018 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.19) 2017 Modelled IHME, GBD 2019 (accessed 2022)
0.16 (0.13 - 0.19) 2016 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.13 - 0.19) 2015 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.13 - 0.19) 2014 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2013 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2012 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2011 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2010 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.19) 2009 Modelled IHME, GBD 2019 (accessed 2022)
0.16 (0.13 - 0.19) 2008 Modelled IHME, GBD 2019 (accessed 2022)
0.17 (0.14 - 0.21) 2007 Modelled IHME, GBD 2019 (accessed 2022)
0.19 (0.15 - 0.22) 2006 Modelled IHME, GBD 2019 (accessed 2022)
0.2 (0.16 - 0.24) 2005 Modelled IHME, GBD 2019 (accessed 2022)
0.22 (0.18 - 0.27) 2004 Modelled IHME, GBD 2019 (accessed 2022)
0.26 (0.21 - 0.31) 2003 Modelled IHME, GBD 2019 (accessed 2022)
0.29 (0.24 - 0.35) 2002 Modelled IHME, GBD 2019 (accessed 2022)
0.33 (0.27 - 0.40) 2001 Modelled IHME, GBD 2019 (accessed 2022)
0.36 (0.29 - 0.44) 2000 Modelled IHME, GBD 2019 (accessed 2022)
0.39 (0.31 - 0.47) 1999 Modelled IHME, GBD 2019 (accessed 2022)
0.41 (0.33 - 0.49) 1998 Modelled IHME, GBD 2019 (accessed 2022)
0.42 (0.34 - 0.52) 1997 Modelled IHME, GBD 2019 (accessed 2022)
0.45 (0.36 - 0.55) 1996 Modelled IHME, GBD 2019 (accessed 2022)
0.49 (0.39 - 0.60) 1995 Modelled IHME, GBD 2019 (accessed 2022)
0.6 (0.48 - 0.74) 1994 Modelled IHME, GBD 2019 (accessed 2022)
0.83 (0.66 - 1.01) 1993 Modelled IHME, GBD 2019 (accessed 2022)
1.13 (0.91 - 1.39) 1992 Modelled IHME, GBD 2019 (accessed 2022)
1.5 (1.21 - 1.84) 1991 Modelled IHME, GBD 2019 (accessed 2022)
1.9 (1.52 - 2.33) 1990 Modelled IHME, GBD 2019 (accessed 2022)
0.2 (0.17 - 0.24) 2020 Modelled WHO
Showing out of
Show more
Technical notes

Number of persons living with chronic HBV

National
Download
Value Year Type Source
996,000 (884,000 - 1,116,000) 2016 Modelled Razavi-Shearer et al, 2018
3,578,980 (3,393,270 - 3,800,360) 2019 Modelled IHME, GBD 2019 (accessed 2020)
3,800,740 (3,607,580 - 4,038,170) 2019 Modelled IHME, GBD 2019 (accessed 2022)
3,786,750 (3,595,670 - 4,003,770) 2018 Modelled IHME, GBD 2019 (accessed 2022)
3,786,610 (3,547,340 - 4,022,880) 2017 Modelled IHME, GBD 2019 (accessed 2022)
3,846,450 (3,637,030 - 4,068,660) 2016 Modelled IHME, GBD 2019 (accessed 2022)
3,875,730 (3,658,370 - 4,124,640) 2015 Modelled IHME, GBD 2019 (accessed 2022)
3,850,580 (3,654,000 - 4,078,720) 2014 Modelled IHME, GBD 2019 (accessed 2022)
3,879,060 (3,675,980 - 4,091,460) 2013 Modelled IHME, GBD 2019 (accessed 2022)
3,924,830 (3,706,230 - 4,142,960) 2012 Modelled IHME, GBD 2019 (accessed 2022)
3,950,980 (3,711,290 - 4,179,030) 2011 Modelled IHME, GBD 2019 (accessed 2022)
3,919,650 (3,660,910 - 4,175,690) 2010 Modelled IHME, GBD 2019 (accessed 2022)
3,874,290 (3,630,890 - 4,119,530) 2009 Modelled IHME, GBD 2019 (accessed 2022)
3,865,580 (3,638,600 - 4,104,580) 2008 Modelled IHME, GBD 2019 (accessed 2022)
3,868,140 (3,650,380 - 4,102,310) 2007 Modelled IHME, GBD 2019 (accessed 2022)
3,857,750 (3,635,380 - 4,096,470) 2006 Modelled IHME, GBD 2019 (accessed 2022)
3,809,100 (3,588,980 - 4,055,820) 2005 Modelled IHME, GBD 2019 (accessed 2022)
3,757,870 (3,551,460 - 3,994,610) 2004 Modelled IHME, GBD 2019 (accessed 2022)
3,741,010 (3,544,290 - 3,968,480) 2003 Modelled IHME, GBD 2019 (accessed 2022)
3,734,810 (3,537,940 - 3,964,270) 2002 Modelled IHME, GBD 2019 (accessed 2022)
3,716,830 (3,512,320 - 3,947,860) 2001 Modelled IHME, GBD 2019 (accessed 2022)
3,664,960 (3,449,780 - 3,904,540) 2000 Modelled IHME, GBD 2019 (accessed 2022)
3,606,300 (3,398,590 - 3,836,320) 1999 Modelled IHME, GBD 2019 (accessed 2022)
3,571,980 (3,367,460 - 3,805,890) 1998 Modelled IHME, GBD 2019 (accessed 2022)
3,546,800 (3,336,130 - 3,775,290) 1997 Modelled IHME, GBD 2019 (accessed 2022)
3,516,600 (3,294,870 - 3,749,970) 1996 Modelled IHME, GBD 2019 (accessed 2022)
3,467,000 (3,240,390 - 3,708,720) 1995 Modelled IHME, GBD 2019 (accessed 2022)
3,409,200 (3,196,620 - 3,635,930) 1994 Modelled IHME, GBD 2019 (accessed 2022)
3,361,610 (3,143,870 - 3,580,970) 1993 Modelled IHME, GBD 2019 (accessed 2022)
3,321,110 (3,101,940 - 3,536,440) 1992 Modelled IHME, GBD 2019 (accessed 2022)
3,286,180 (3,056,150 - 3,502,160) 1991 Modelled IHME, GBD 2019 (accessed 2022)
3,254,630 (3,003,040 - 3,479,980) 1990 Modelled IHME, GBD 2019 (accessed 2022)
952,000 (777,000 - 1,037,000) 2022 Modelled Polaris Observatory Collaborators
Showing out of
Show more

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
19.4 (11.80 - 28.70) 2019 Modelled IHME, GBD 2019 (accessed 2020)
31.51 (24.46 - 41.63) 1990 Modelled IHME, GBD 2019 (accessed 2022)
30.46 (23.66 - 39.77) 1991 Modelled IHME, GBD 2019 (accessed 2022)
29.51 (23.05 - 38.30) 1992 Modelled IHME, GBD 2019 (accessed 2022)
29.31 (22.91 - 37.88) 1993 Modelled IHME, GBD 2019 (accessed 2022)
29.08 (22.70 - 37.79) 1994 Modelled IHME, GBD 2019 (accessed 2022)
28.24 (22.01 - 36.51) 1995 Modelled IHME, GBD 2019 (accessed 2022)
27.79 (21.59 - 35.96) 1996 Modelled IHME, GBD 2019 (accessed 2022)
27.76 (21.66 - 36.12) 1997 Modelled IHME, GBD 2019 (accessed 2022)
27.41 (21.22 - 35.86) 1999 Modelled IHME, GBD 2019 (accessed 2022)
27.58 (21.42 - 36.15) 1998 Modelled IHME, GBD 2019 (accessed 2022)
26.61 (20.47 - 34.86) 2000 Modelled IHME, GBD 2019 (accessed 2022)
26.76 (20.65 - 35.26) 2001 Modelled IHME, GBD 2019 (accessed 2022)
25.89 (19.72 - 34.36) 2002 Modelled IHME, GBD 2019 (accessed 2022)
24.71 (18.51 - 33.22) 2003 Modelled IHME, GBD 2019 (accessed 2022)
20.65 (15.13 - 28.20) 2006 Modelled IHME, GBD 2019 (accessed 2022)
22.77 (16.78 - 31.03) 2004 Modelled IHME, GBD 2019 (accessed 2022)
21.3 (15.59 - 29.08) 2005 Modelled IHME, GBD 2019 (accessed 2022)
20.12 (14.72 - 27.55) 2007 Modelled IHME, GBD 2019 (accessed 2022)
20.09 (14.53 - 27.61) 2008 Modelled IHME, GBD 2019 (accessed 2022)
20.25 (14.51 - 27.97) 2009 Modelled IHME, GBD 2019 (accessed 2022)
20.08 (14.24 - 27.71) 2010 Modelled IHME, GBD 2019 (accessed 2022)
19.91 (14.04 - 27.57) 2011 Modelled IHME, GBD 2019 (accessed 2022)
19.88 (13.91 - 27.40) 2012 Modelled IHME, GBD 2019 (accessed 2022)
19.22 (13.47 - 26.25) 2013 Modelled IHME, GBD 2019 (accessed 2022)
19.15 (13.30 - 26.43) 2014 Modelled IHME, GBD 2019 (accessed 2022)
19.47 (13.22 - 27.21) 2015 Modelled IHME, GBD 2019 (accessed 2022)
19.53 (13.05 - 27.53) 2016 Modelled IHME, GBD 2019 (accessed 2022)
19.34 (12.34 - 27.82) 2017 Modelled IHME, GBD 2019 (accessed 2022)
19.37 (11.77 - 28.65) 2019 Modelled IHME, GBD 2019 (accessed 2022)
19.35 (12.13 - 28.25) 2018 Modelled IHME, GBD 2019 (accessed 2022)
4.9 (2.48 - 6.03) 2022 Survey/reported Communication with Egyptian Liver Institute, November 2023
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
6,621 2016 Modelled WHO
17,552 (13,623 - 23,187) 1990 Modelled IHME, GBD 2019 (accessed 2022)
17,308 (13,440 - 22,596) 1991 Modelled IHME, GBD 2019 (accessed 2022)
17,094 (13,351 - 22,188) 1992 Modelled IHME, GBD 2019 (accessed 2022)
17,303 (13,526 - 22,362) 1993 Modelled IHME, GBD 2019 (accessed 2022)
17,492 (13,655 - 22,733) 1994 Modelled IHME, GBD 2019 (accessed 2022)
17,304 (13,487 - 22,373) 1995 Modelled IHME, GBD 2019 (accessed 2022)
17,357 (13,485 - 22,461) 1996 Modelled IHME, GBD 2019 (accessed 2022)
17,676 (13,793 - 23,003) 1997 Modelled IHME, GBD 2019 (accessed 2022)
17,913 (13,914 - 23,486) 1998 Modelled IHME, GBD 2019 (accessed 2022)
18,170 (14,071 - 23,772) 1999 Modelled IHME, GBD 2019 (accessed 2022)
18,012 (13,856 - 23,596) 2000 Modelled IHME, GBD 2019 (accessed 2022)
18,504 (14,275 - 24,377) 2001 Modelled IHME, GBD 2019 (accessed 2022)
18,284 (13,924 - 24,261) 2002 Modelled IHME, GBD 2019 (accessed 2022)
16,774 (12,362 - 22,856) 2004 Modelled IHME, GBD 2019 (accessed 2022)
17,822 (13,350 - 23,959) 2003 Modelled IHME, GBD 2019 (accessed 2022)
15,879 (11,637 - 21,683) 2006 Modelled IHME, GBD 2019 (accessed 2022)
15,813 (11,566 - 21,645) 2007 Modelled IHME, GBD 2019 (accessed 2022)
16,027 (11,732 - 21,886) 2005 Modelled IHME, GBD 2019 (accessed 2022)
16,132 (11,663 - 22,166) 2008 Modelled IHME, GBD 2019 (accessed 2022)
16,614 (11,901 - 22,942) 2009 Modelled IHME, GBD 2019 (accessed 2022)
16,824 (11,929 - 23,211) 2010 Modelled IHME, GBD 2019 (accessed 2022)
17,033 (12,006 - 23,585) 2011 Modelled IHME, GBD 2019 (accessed 2022)
17,127 (12,002 - 23,391) 2013 Modelled IHME, GBD 2019 (accessed 2022)
17,362 (12,144 - 23,928) 2012 Modelled IHME, GBD 2019 (accessed 2022)
18,024 (12,239 - 25,187) 2015 Modelled IHME, GBD 2019 (accessed 2022)
17,398 (12,084 - 24,013) 2014 Modelled IHME, GBD 2019 (accessed 2022)
18,406 (12,296 - 25,947) 2016 Modelled IHME, GBD 2019 (accessed 2022)
18,543 (11,837 - 26,676) 2017 Modelled IHME, GBD 2019 (accessed 2022)
18,860 (11,828 - 27,543) 2018 Modelled IHME, GBD 2019 (accessed 2022)
19,190 (11,665 - 28,385) 2019 Modelled IHME, GBD 2019 (accessed 2022)
19,190 (11,665 - 28,385) 2019 Modelled IHME, GBD 2019 (accessed 2020)
5,000 2022 Survey/reported Communication with Egyptian Liver Institute, November 2023
Showing out of
Show more
Technical notes

Percent of cases of hepatocellular carcinoma attributable to HBV

National
Download
Value (%) Year Type Source
1 2016 Survey/reported Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
16 (11 - 24) 1990 Modelled IHME, GBD 2019 (accessed 2022)
17 (12 - 25) 1991 Modelled IHME, GBD 2019 (accessed 2022)
18 (12 - 26) 1992 Modelled IHME, GBD 2019 (accessed 2022)
18 (13 - 26) 1993 Modelled IHME, GBD 2019 (accessed 2022)
19 (13 - 27) 1994 Modelled IHME, GBD 2019 (accessed 2022)
20 (13 - 28) 1995 Modelled IHME, GBD 2019 (accessed 2022)
20 (14 - 29) 1996 Modelled IHME, GBD 2019 (accessed 2022)
21 (14 - 29) 1997 Modelled IHME, GBD 2019 (accessed 2022)
21 (14 - 29) 1998 Modelled IHME, GBD 2019 (accessed 2022)
21 (15 - 29) 1999 Modelled IHME, GBD 2019 (accessed 2022)
21 (15 - 30) 2000 Modelled IHME, GBD 2019 (accessed 2022)
22 (15 - 32) 2001 Modelled IHME, GBD 2019 (accessed 2022)
23 (16 - 32) 2002 Modelled IHME, GBD 2019 (accessed 2022)
24 (16 - 34) 2004 Modelled IHME, GBD 2019 (accessed 2022)
23 (16 - 32) 2003 Modelled IHME, GBD 2019 (accessed 2022)
27 (19 - 39) 2007 Modelled IHME, GBD 2019 (accessed 2022)
26 (18 - 38) 2006 Modelled IHME, GBD 2019 (accessed 2022)
25 (17 - 36) 2005 Modelled IHME, GBD 2019 (accessed 2022)
28 (20 - 40) 2008 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 45) 2009 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 45) 2010 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 46) 2011 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 46) 2013 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 46) 2012 Modelled IHME, GBD 2019 (accessed 2022)
30 (20 - 46) 2015 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 46) 2014 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 48) 2017 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 47) 2016 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 48) 2018 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 49) 2019 Modelled IHME, GBD 2019 (accessed 2022)
13 (9 - 19) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
91 2019 Survey/reported WHO/UNICEF
89 2018 Survey/reported WHO/UNICEF
84 2017 Survey/reported WHO/UNICEF
92 2020 Survey/reported WHO/UNICEF
93 2021 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

National
Download
Value (%) Year Type Source
95 2017 Survey/reported WHO Immunization Data portal
Infants
Download
Value (%) Year Type Source
95 2019 Survey/reported WHO/UNICEF
94 2020 Survey/reported WHO/UNICEF
96 2021 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Proportion of persons living with HBV diagnosed

National
Download
Value (%) Year Type Source
6 2022 Modelled Polaris Observatory Collaborators

Proportion of diagnosed HBV persons receiving appropriate treatment

National
Download
Value (%) Year Type Source
25 2021 Modelled Communication with Egyptian National Liver Institute
10 2022 Modelled Polaris Observatory Collaborators
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Source:
National prevalence survey within the last 5 years
Not Adopted
Communication with Professor Imam Waked, Egyptian National Liver Institute (NLI)
Estimates of economic burden
Not Adopted
World Bank (2017)
System for monitoring testing and treatment
Adopted
Mohamed, M. K., et al (2005)
HepB birth dose policy
Yes
Source: WHO
Year of birth dose introduction
2015
Source: WHO
Recommendations for HBV testing of pregnant women
Adopted
El-Akel,W., et al. (2017)
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
Communication with Egyptian National Liver Institute
HBV testing policy
Risk-based
El-Akel,W., et al. (2017)
No patient co-pays for HBsAg testing
Adopted
Waked, I et al (2014)
National treatment guidelines exist
Adopted
Communication with Egyptian National Liver Institute
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Not Adopted
El-Akel, W., et al. (2017)
Simplified care: No treatment co-pays
Adopted
Egypt Ministry of Health and Population
Adult HBV vaccination policy for high-risk populations
Partially Adopted
Communication with Professor Manal Hamdy El-Sayed
Public budget line for testing and treatment
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2020
Source:
National prevalence survey within the last 5 years
Not Adopted
Waked, I. et al
Estimates of economic burden
Adopted
Waked, I et al (2014)
System for monitoring testing and treatment
Adopted
Mohamed, M. K., et al
Recommendations for HCV testing of pregnant women
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)
Registration of originator HCV DAAs
Adopted
WHO (2020)
Eligible for HCV generic medicines
Source: MPP
Registration of generic HCV DAAs
Adopted
HepCoalition
Licensed point-of-care PCR testing to detect HCV
Adopted
Communication with Egyptian National Liver Institute
HCV testing policy
Universal
Source:
No patient co-pays for anti-HCV testing
Adopted
Waked, I et al (2014)
National treatment guidelines exist
Communication with Egyptian National Liver Institute
Simplified care: Less than 2 clinic visits during treatment
Adopted
Presentation by Dr. Mohamad Hassany (2020)
Simplified care: Non-specialists can prescribe treatment
Adopted
Communication with Egyptian National Liver Institute
Simplified care: No treatment co-pays
Adopted
WHO (2020)
No fibrosis restrictions
Adopted
Egypt Ministry of Health and Population
No sobriety restrictions
Adopted
Communication with Egyptian National Liver Institute
No genotyping
Adopted
Communication with Egyptian National Liver Institute
National policy for harm reduction for persons who inject drugs
Partially Adopted
Georgetown HIV Policy Lab
National policy for syringe exchange in federal prisons
Georgetown HIV Policy Lab
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
No
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
No
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Source: WHO
Public budget line for testing and treatment
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
6 2015 Survey/reported Egypt Ministry of Health et al, 2015
7.3 2013 Modelled Waked et al, 2013
8 2008 Survey/reported El-Zanaty F and Way A, 2008
15 1999 Survey/reported Abdel-Aziz F et al, 2000
0.4 2019 Modelled Communication with Prof Imam Waked, National Liver Institue, Egyptian National Committee for Viral Hepatitis
6.3 (4.50 - 6.70) 2015 Modelled Blach et al, 2017
10 (7 - 12.20) 2014 Survey/reported Gower et al, 2014
2.38 (1.74 - 3.22) 2019 Modelled IHME, GBD 2019 (accessed 2022)
3.35 (2.65 - 4.25) 2018 Modelled IHME, GBD 2019 (accessed 2022)
4.02 (3.21 - 4.99) 2017 Modelled IHME, GBD 2019 (accessed 2022)
4.41 (3.56 - 5.41) 2016 Modelled IHME, GBD 2019 (accessed 2022)
4.71 (3.84 - 5.74) 2015 Modelled IHME, GBD 2019 (accessed 2022)
5.03 (4.15 - 6.02) 2014 Modelled IHME, GBD 2019 (accessed 2022)
5.37 (4.47 - 6.37) 2013 Modelled IHME, GBD 2019 (accessed 2022)
5.67 (4.75 - 6.70) 2012 Modelled IHME, GBD 2019 (accessed 2022)
5.91 (4.97 - 6.95) 2011 Modelled IHME, GBD 2019 (accessed 2022)
6.03 (5.06 - 7.12) 2010 Modelled IHME, GBD 2019 (accessed 2022)
6.08 (5.14 - 7.13) 2009 Modelled IHME, GBD 2019 (accessed 2022)
6.14 (5.22 - 7.19) 2008 Modelled IHME, GBD 2019 (accessed 2022)
6.18 (5.22 - 7.23) 2007 Modelled IHME, GBD 2019 (accessed 2022)
6.19 (5.20 - 7.27) 2006 Modelled IHME, GBD 2019 (accessed 2022)
6.15 (5.16 - 7.29) 2005 Modelled IHME, GBD 2019 (accessed 2022)
6.02 (5.05 - 7.15) 2004 Modelled IHME, GBD 2019 (accessed 2022)
5.81 (4.87 - 6.94) 2003 Modelled IHME, GBD 2019 (accessed 2022)
5.6 (4.67 - 6.74) 2002 Modelled IHME, GBD 2019 (accessed 2022)
5.43 (4.51 - 6.56) 2001 Modelled IHME, GBD 2019 (accessed 2022)
5.35 (4.42 - 6.49) 2000 Modelled IHME, GBD 2019 (accessed 2022)
5.34 (4.43 - 6.49) 1999 Modelled IHME, GBD 2019 (accessed 2022)
5.36 (4.45 - 6.49) 1998 Modelled IHME, GBD 2019 (accessed 2022)
5.37 (4.46 - 6.52) 1997 Modelled IHME, GBD 2019 (accessed 2022)
5.4 (4.47 - 6.57) 1996 Modelled IHME, GBD 2019 (accessed 2022)
5.42 (4.47 - 6.64) 1995 Modelled IHME, GBD 2019 (accessed 2022)
5.46 (4.51 - 6.67) 1994 Modelled IHME, GBD 2019 (accessed 2022)
5.53 (4.57 - 6.76) 1993 Modelled IHME, GBD 2019 (accessed 2022)
5.62 (4.63 - 6.89) 1992 Modelled IHME, GBD 2019 (accessed 2022)
5.73 (4.71 - 7.05) 1991 Modelled IHME, GBD 2019 (accessed 2022)
5.85 (4.79 - 7.25) 1990 Modelled IHME, GBD 2019 (accessed 2022)
1.98 (1.28 - 2.86) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
1.38 (0.99 - 1.49) 2019 Modelled Dugan et al., 2021
Technical notes

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
6.3 2015 Survey/reported Egypt Ministry of Health et al, 2015
12 2008 Survey/reported El-Zanaty F and Way A, 2008
23.7 1999 Survey/reported Abdel-Aziz F et al, 2000
14.7 (13.90 - 15.50) 2008 Survey/reported Guerra et al, 2012
14.7 (10.30 - 18) 2014 Survey/reported Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
49.4 (35.80 - 63) 1995 Modelled Nelson P et al, 2011
Technical notes

Number of persons living with chronic HCV (RNA+/cAg)

National
Download
Value Year Type Source
5,625,000 (4,007,000 - 6,044,000) 2015 Modelled Blach et al, 2017
450,000 2021 Modelled Communication with Egyptian National Liver Institute
3,138,890 (2,569,950 - 3,901,850) 1990 Modelled IHME, GBD 2019 (accessed 2022)
3,137,290 (2,576,330 - 3,860,920) 1991 Modelled IHME, GBD 2019 (accessed 2022)
3,139,450 (2,581,510 - 3,856,420) 1992 Modelled IHME, GBD 2019 (accessed 2022)
3,149,370 (2,598,680 - 3,850,940) 1993 Modelled IHME, GBD 2019 (accessed 2022)
3,169,650 (2,621,870 - 3,847,390) 1994 Modelled IHME, GBD 2019 (accessed 2022)
3,205,740 (2,642,500 - 3,897,580) 1995 Modelled IHME, GBD 2019 (accessed 2022)
3,250,710 (2,681,640 - 3,947,630) 1996 Modelled IHME, GBD 2019 (accessed 2022)
3,296,300 (2,732,420 - 4,005,230) 1997 Modelled IHME, GBD 2019 (accessed 2022)
3,346,880 (2,778,990 - 4,052,170) 1998 Modelled IHME, GBD 2019 (accessed 2022)
3,405,490 (2,826,800 - 4,124,430) 1999 Modelled IHME, GBD 2019 (accessed 2022)
3,477,330 (2,871,650 - 4,226,570) 2000 Modelled IHME, GBD 2019 (accessed 2022)
3,602,570 (2,989,250 - 4,365,200) 2001 Modelled IHME, GBD 2019 (accessed 2022)
3,797,530 (3,162,110 - 4,580,810) 2002 Modelled IHME, GBD 2019 (accessed 2022)
4,028,520 (3,367,610 - 4,823,640) 2003 Modelled IHME, GBD 2019 (accessed 2022)
4,257,310 (3,571,530 - 5,064,580) 2004 Modelled IHME, GBD 2019 (accessed 2022)
4,443,230 (3,731,790 - 5,267,590) 2005 Modelled IHME, GBD 2019 (accessed 2022)
4,569,020 (3,838,300 - 5,373,070) 2006 Modelled IHME, GBD 2019 (accessed 2022)
4,657,210 (3,939,440 - 5,462,500) 2007 Modelled IHME, GBD 2019 (accessed 2022)
4,721,010 (3,987,880 - 5,524,300) 2008 Modelled IHME, GBD 2019 (accessed 2022)
4,772,680 (4,037,360 - 5,596,160) 2009 Modelled IHME, GBD 2019 (accessed 2022)
4,826,930 (4,058,190 - 5,707,110) 2010 Modelled IHME, GBD 2019 (accessed 2022)
4,827,170 (4,067,810 - 5,685,030) 2011 Modelled IHME, GBD 2019 (accessed 2022)
4,725,460 (3,962,350 - 5,587,440) 2012 Modelled IHME, GBD 2019 (accessed 2022)
4,554,920 (3,803,030 - 5,406,320) 2013 Modelled IHME, GBD 2019 (accessed 2022)
4,351,040 (3,594,010 - 5,211,520) 2014 Modelled IHME, GBD 2019 (accessed 2022)
4,151,620 (3,376,910 - 5,057,950) 2015 Modelled IHME, GBD 2019 (accessed 2022)
3,951,820 (3,192,990 - 4,844,840) 2016 Modelled IHME, GBD 2019 (accessed 2022)
3,660,010 (2,915,820 - 4,508,990) 2017 Modelled IHME, GBD 2019 (accessed 2022)
3,099,710 (2,449,950 - 3,917,090) 2018 Modelled IHME, GBD 2019 (accessed 2022)
1,963,340 (1,272,010 - 2,833,450) 2019 Modelled IHME, GBD 2019 (accessed 2020)
2,239,660 (1,627,680 - 3,026,590) 2019 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value Year Type Source
345,000 (246,000 - 371,000) 2019 Modelled Dugan et al., 2021

Number of new cases of HCV

National
Download
Value Year Type Source
6,000 2021 Modelled Communication with Egyptian National Liver Institute

HCV-related death rate

National
Download
Value (Deaths per 100,000) Year Type Source
35.9 (24.20 - 48.90) 2019 Modelled IHME, GBD 2019 (accessed 2020)
31.56 (25.22 - 38.31) 1990 Modelled IHME, GBD 2019 (accessed 2022)
30.81 (24.74 - 37.41) 1991 Modelled IHME, GBD 2019 (accessed 2022)
29.97 (24.13 - 36.24) 1992 Modelled IHME, GBD 2019 (accessed 2022)
29.77 (24.28 - 35.95) 1994 Modelled IHME, GBD 2019 (accessed 2022)
29.9 (24.36 - 35.80) 1993 Modelled IHME, GBD 2019 (accessed 2022)
29.04 (23.63 - 35.07) 1995 Modelled IHME, GBD 2019 (accessed 2022)
28.69 (23.29 - 34.70) 1996 Modelled IHME, GBD 2019 (accessed 2022)
28.68 (23.23 - 34.62) 1997 Modelled IHME, GBD 2019 (accessed 2022)
28.52 (23.05 - 34.71) 1998 Modelled IHME, GBD 2019 (accessed 2022)
28.39 (23 - 34.35) 1999 Modelled IHME, GBD 2019 (accessed 2022)
27.73 (22.48 - 33.65) 2000 Modelled IHME, GBD 2019 (accessed 2022)
29.04 (23.48 - 35.31) 2001 Modelled IHME, GBD 2019 (accessed 2022)
30.51 (24.65 - 37.36) 2002 Modelled IHME, GBD 2019 (accessed 2022)
32.35 (25.84 - 39.82) 2003 Modelled IHME, GBD 2019 (accessed 2022)
33.14 (26.53 - 40.86) 2004 Modelled IHME, GBD 2019 (accessed 2022)
33.04 (26.40 - 40.55) 2006 Modelled IHME, GBD 2019 (accessed 2022)
33.08 (26.52 - 40.33) 2005 Modelled IHME, GBD 2019 (accessed 2022)
32.97 (26.45 - 40.11) 2007 Modelled IHME, GBD 2019 (accessed 2022)
33.49 (26.76 - 40.69) 2008 Modelled IHME, GBD 2019 (accessed 2022)
34.66 (27.42 - 42.26) 2009 Modelled IHME, GBD 2019 (accessed 2022)
34.74 (27.18 - 42.41) 2010 Modelled IHME, GBD 2019 (accessed 2022)
34.91 (27.25 - 42.85) 2011 Modelled IHME, GBD 2019 (accessed 2022)
35.33 (27.27 - 43.31) 2012 Modelled IHME, GBD 2019 (accessed 2022)
34.68 (27.01 - 41.95) 2013 Modelled IHME, GBD 2019 (accessed 2022)
35.01 (27.04 - 42.60) 2014 Modelled IHME, GBD 2019 (accessed 2022)
35.86 (27.03 - 44.49) 2015 Modelled IHME, GBD 2019 (accessed 2022)
35.64 (25.68 - 47.20) 2017 Modelled IHME, GBD 2019 (accessed 2022)
36.03 (26.43 - 46.28) 2016 Modelled IHME, GBD 2019 (accessed 2022)
35.86 (24.24 - 48.95) 2019 Modelled IHME, GBD 2019 (accessed 2022)
35.72 (24.35 - 48.80) 2018 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
59,475 2016 Modelled WHO
18,000 2019 Modelled Communication with Egyptian National Liver Institute
35,523 (24,016 - 48,494) 2019 Modelled IHME, GBD 2019 (accessed 2022)
35,523 (24,016 - 48,494) 2019 Modelled IHME, GBD 2019 (accessed 2020)
34,829 (23,744 - 47,578) 2018 Modelled IHME, GBD 2019 (accessed 2022)
34,179 (24,621 - 45,262) 2017 Modelled IHME, GBD 2019 (accessed 2022)
33,961 (24,911 - 43,625) 2016 Modelled IHME, GBD 2019 (accessed 2022)
33,198 (25,023 - 41,187) 2015 Modelled IHME, GBD 2019 (accessed 2022)
31,809 (24,572 - 38,708) 2014 Modelled IHME, GBD 2019 (accessed 2022)
30,896 (24,064 - 37,371) 2013 Modelled IHME, GBD 2019 (accessed 2022)
30,852 (23,815 - 37,820) 2012 Modelled IHME, GBD 2019 (accessed 2022)
29,860 (23,306 - 36,658) 2011 Modelled IHME, GBD 2019 (accessed 2022)
29,102 (22,774 - 35,531) 2010 Modelled IHME, GBD 2019 (accessed 2022)
28,433 (22,494 - 34,664) 2009 Modelled IHME, GBD 2019 (accessed 2022)
26,886 (21,488 - 32,667) 2008 Modelled IHME, GBD 2019 (accessed 2022)
25,907 (20,781 - 31,513) 2007 Modelled IHME, GBD 2019 (accessed 2022)
25,405 (20,298 - 31,182) 2006 Modelled IHME, GBD 2019 (accessed 2022)
24,895 (19,962 - 30,349) 2005 Modelled IHME, GBD 2019 (accessed 2022)
24,410 (19,546 - 30,097) 2004 Modelled IHME, GBD 2019 (accessed 2022)
23,333 (18,636 - 28,717) 2003 Modelled IHME, GBD 2019 (accessed 2022)
21,543 (17,403 - 26,380) 2002 Modelled IHME, GBD 2019 (accessed 2022)
20,078 (16,233 - 24,415) 2001 Modelled IHME, GBD 2019 (accessed 2022)
18,770 (15,215 - 22,781) 2000 Modelled IHME, GBD 2019 (accessed 2022)
18,826 (15,250 - 22,771) 1999 Modelled IHME, GBD 2019 (accessed 2022)
18,528 (14,973 - 22,548) 1998 Modelled IHME, GBD 2019 (accessed 2022)
18,262 (14,790 - 22,048) 1997 Modelled IHME, GBD 2019 (accessed 2022)
17,921 (14,546 - 21,672) 1996 Modelled IHME, GBD 2019 (accessed 2022)
17,795 (14,481 - 21,490) 1995 Modelled IHME, GBD 2019 (accessed 2022)
17,910 (14,605 - 21,622) 1994 Modelled IHME, GBD 2019 (accessed 2022)
17,650 (14,381 - 21,137) 1993 Modelled IHME, GBD 2019 (accessed 2022)
17,359 (13,980 - 20,991) 1992 Modelled IHME, GBD 2019 (accessed 2022)
17,505 (14,055 - 21,256) 1991 Modelled IHME, GBD 2019 (accessed 2022)
17,577 (14,048 - 21,337) 1990 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

Percent of cases of hepatocellular carcinoma attributable to HCV

National
Download
Value (%) Year Type Source
84 2016 Survey/reported Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
76 (59 - 92) 1992 Modelled IHME, GBD 2019 (accessed 2022)
72 (54 - 90) 1990 Modelled IHME, GBD 2019 (accessed 2022)
75 (57 - 93) 1991 Modelled IHME, GBD 2019 (accessed 2022)
82 (67 - 98) 1995 Modelled IHME, GBD 2019 (accessed 2022)
77 (62 - 93) 1993 Modelled IHME, GBD 2019 (accessed 2022)
79 (64 - 94) 1994 Modelled IHME, GBD 2019 (accessed 2022)
86 (70 - 102) 1996 Modelled IHME, GBD 2019 (accessed 2022)
92 (76 - 109) 1999 Modelled IHME, GBD 2019 (accessed 2022)
88 (72 - 104) 1997 Modelled IHME, GBD 2019 (accessed 2022)
90 (73 - 107) 1998 Modelled IHME, GBD 2019 (accessed 2022)
96 (79 - 112) 2000 Modelled IHME, GBD 2019 (accessed 2022)
102 (84 - 119) 2001 Modelled IHME, GBD 2019 (accessed 2022)
107 (88 - 125) 2002 Modelled IHME, GBD 2019 (accessed 2022)
117 (97 - 137) 2004 Modelled IHME, GBD 2019 (accessed 2022)
111 (92 - 131) 2003 Modelled IHME, GBD 2019 (accessed 2022)
129 (107 - 153) 2006 Modelled IHME, GBD 2019 (accessed 2022)
122 (101 - 143) 2005 Modelled IHME, GBD 2019 (accessed 2022)
143 (118 - 168) 2008 Modelled IHME, GBD 2019 (accessed 2022)
137 (113 - 161) 2007 Modelled IHME, GBD 2019 (accessed 2022)
158 (129 - 187) 2009 Modelled IHME, GBD 2019 (accessed 2022)
158 (128 - 191) 2010 Modelled IHME, GBD 2019 (accessed 2022)
160 (128 - 197) 2011 Modelled IHME, GBD 2019 (accessed 2022)
159 (128 - 197) 2013 Modelled IHME, GBD 2019 (accessed 2022)
159 (127 - 198) 2012 Modelled IHME, GBD 2019 (accessed 2022)
160 (126 - 200) 2014 Modelled IHME, GBD 2019 (accessed 2022)
156 (120 - 198) 2015 Modelled IHME, GBD 2019 (accessed 2022)
156 (119 - 204) 2016 Modelled IHME, GBD 2019 (accessed 2022)
156 (118 - 204) 2017 Modelled IHME, GBD 2019 (accessed 2022)
155 (115 - 206) 2018 Modelled IHME, GBD 2019 (accessed 2022)
154 (114 - 206) 2019 Modelled IHME, GBD 2019 (accessed 2022)
63 (54 - 71) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Number of persons treated for HCV

National
Download
Value Year Type Source
1,600,000 2020 Survey/reported Communication with Prof Waked, 2020
1,600,000 2020 Survey/reported Communication with Professor Imam Waked, Egyptian National Liver Institute
Showing out of
Show more
Ages 15-18
Download
Value Year Type Source
12,000 2020 Survey/reported Communication with Prof Waked, 2020
Technical notes

Cumulative number of persons treated for HCV

National
Download
Value Year Type Source
30,000 2014 Survey/reported WHO, 2021
100,000 2015 Survey/reported WHO, 2021
700,000 2016 Survey/reported WHO, 2021
2,236,670 2018 Survey/reported WHO, 2021
4,000,000 2020 Survey/reported Egypt Today Staff
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016

Proportion of persons living with HCV diagnosed

12 years of age and older
Download
Value (%) Year Type Source
96 2021 Modelled Communication with Egyptian National Liver Institute

Price of HCV cure (Cheapest price in private sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
18 2019 Survey/reported WHO, 2021

Price of HCV cure (Average price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
33 2019 Survey/reported WHO, 2021

Price of HCV cure (Cheapest price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
18 2019 Survey/reported WHO, 2021

Price of HCV cure (Average price in private sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
54 2019 Survey/reported WHO, 2021
HBV National Action Plan
HBV elimination goal
Source:
National prevalence survey within the last 5 years
Not Adopted
Communication with Professor Imam Waked, Egyptian National Liver Institute (NLI)
Estimates of economic burden
Not Adopted
World Bank (2017)
System for monitoring testing and treatment
Adopted
Mohamed, M. K., et al (2005)
HepB birth dose policy
Yes
Source: WHO
Year of birth dose introduction
2015
Source: WHO
Recommendations for HBV testing of pregnant women
Adopted
El-Akel,W., et al. (2017)
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
Communication with Egyptian National Liver Institute
HBV testing policy
Risk-based
El-Akel,W., et al. (2017)
No patient co-pays for HBsAg testing
Adopted
Waked, I et al (2014)
National treatment guidelines exist
Adopted
Communication with Egyptian National Liver Institute
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Not Adopted
El-Akel, W., et al. (2017)
Simplified care: No treatment co-pays
Adopted
Egypt Ministry of Health and Population
Adult HBV vaccination policy for high-risk populations
Partially Adopted
Communication with Professor Manal Hamdy El-Sayed
Public budget line for testing and treatment
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2020
Source:
National prevalence survey within the last 5 years
Not Adopted
Waked, I. et al
Estimates of economic burden
Adopted
Waked, I et al (2014)
System for monitoring testing and treatment
Adopted
Mohamed, M. K., et al
Recommendations for HCV testing of pregnant women
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)
Registration of originator HCV DAAs
Adopted
WHO (2020)
Eligible for HCV generic medicines
Source: MPP
Registration of generic HCV DAAs
Adopted
HepCoalition
Licensed point-of-care PCR testing to detect HCV
Adopted
Communication with Egyptian National Liver Institute
HCV testing policy
Universal
Source:
No patient co-pays for anti-HCV testing
Adopted
Waked, I et al (2014)
National treatment guidelines exist
Communication with Egyptian National Liver Institute
Simplified care: Less than 2 clinic visits during treatment
Adopted
Presentation by Dr. Mohamad Hassany (2020)
Simplified care: Non-specialists can prescribe treatment
Adopted
Communication with Egyptian National Liver Institute
Simplified care: No treatment co-pays
Adopted
WHO (2020)
No fibrosis restrictions
Adopted
Egypt Ministry of Health and Population
No sobriety restrictions
Adopted
Communication with Egyptian National Liver Institute
No genotyping
Adopted
Communication with Egyptian National Liver Institute
National policy for harm reduction for persons who inject drugs
Partially Adopted
Georgetown HIV Policy Lab
National policy for syringe exchange in federal prisons
Georgetown HIV Policy Lab
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
No
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
No
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Source: WHO
Public budget line for testing and treatment
Adopted
Hassanin, A., Kamel, S., Waked, I., & Fort, M (2021)

Overview

HBV elimination goal
HCV elimination goal
Year of goal
2020

Prevalence (national)

Modelled

HBV (HBsAg+)
0.9 (%)
2022
(0.7 - 1.1(%))
Polaris Observatory Collaborators
HCV (RNA/cAg+)
0.4 (%)
2019
Communication with Prof Imam Waked, National Liver Institue, Egyptian National Committee for Viral Hepatitis

Survey/surveillance

HBV (HBsAg+)
1.4 (%)
2015
(1.2 - 1.6(%))
Ismail et al, 2017
HCV (anti-HCV)
6.3 (%)
2015
Egypt Ministry of Health et al, 2015

Hepatitis related deaths (national)

Modelled

HBV
19,190
2019
(11,665 - 28,385)
IHME, GBD 2019 (accessed 2022)

Survey/surveillance

HBV
5,000
2022
Communication with Egyptian Liver Institute, November 2023
HBV chart

Modelled

HCV
18,000
2019
Communication with Egyptian National Liver Institute

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.20 (%)
2020, latest modelled
(0.17 - 0.24(%))
WHO

Prevalence PWID

HCV
49.40 (%)
1995, latest modelled
(35.80 - 63(%))
Nelson P et al, 2011

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
93 (%)
2021
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Download National Hepatitis Elimination Profile (N-HEP)

Latest news

View all

Action plan

View all

Elimination champion

News

Action plans

Resources

Programs

Partners